Overview on nanoparticulate formulations for 5-fluorouracil delivery in colorectal cancer treatment
Keywords:
5-fluorouracil, colorectal cancer, nanoparticles.Abstract
5-Fluorouracil (5-FU) is an antimetabolite drug used to treat various cancer types, especially colon cancer. Its mechanism of action includes the inhibition of the biosynthetic processes in proliferating cells by inhibiting the normal function of DNA and RNA. 5-FU has a short half-life since 80% of the administered drug is catabolized in the liver. Moreover, the therapies based on the 5-FU administration are accompanied by severe side effects such as immunosuppression, cardiotoxicity, and neurotoxicity. Therefore, the use of the nanoparticle-encapsulated 5-FU can target efficiently colorectal cancer, could reduce the major drawbacks of conventional administration of 5-FU and also increase the drug lifetime and its tumour accumulation, and finally 5-FU therapeutic index will be enhanced. To this end, this article aims to review the recent research regarding nanoparticles encapsulating 5-FU for colorectal cancer targeted therapy.
References
Anitha, A., Deepa, N., Chennazhi, K., Lakshmanan, V. -K., Jayakumar, R. (2014) Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment, BBA Gen. Subjects, 1840(9), 2730-2743
Arias, J. L. (2008) Novel strategies to improve the anticancer action of 5-fluorouracil by using drug delivery systems, Molecules, 13(10), 2340-2369
Banciu, M. (2007) Liposomal targeting of glucocorticoids to inhibit tumor angiogenesis, PrintPartners Ipskamp, Enschede, Olanda, 17
Cheng, M. -R., Li, Q., Wan, T., He, B., Han, J., Chen, H. -X., Yang, F. -X., Wang, W., Xu, H. -Z., Ye, T., Zha, B. -B. (2012a) Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects, World J. Gastroenterol., 18(42), 6076-6087
Cheng, M., He, B., Wan, T., Zhu, W., Han, J., Zha, B., Chen, H., Yang, F., Li, Q., Wang, W. (2012b) 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model, PloS one, 7(10), e47115
Clares, B., Biedma-Ortiz, R. A., Sáez-Fernández, E., Prados, J. C., Melguizo, C., Cabeza, L., Ortiz, R., Arias, J. L. (2013) Nano-engineering of 5-fluorouracil-loaded magnetoliposomes for combined hyperthermia and chemotherapy against colon cancer, Eur. J. Pharm. Biopharm., 85(3), 329-338
Dhawale, S., Bankar, A., Patro, M. (2010) Formulation and evaluation porous microspheres of 5-fluorouracil for colon targeting, Int. J. Pharm. Tech. Res., 2(2), 1112-1118
Fata, F., Ron, I. G., Kemeny, N., O'Reilly, E., Klimstra, D., Kelsen, D. P. (1999) 5‐Fluorouracil‐induced small bowel toxicity in patients with colorectal carcinoma, Cancer, 86(7), 1129-1134
Jain, A., Jain, S. K. (2008) In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors, Eur. J. Pharm. Sci., 35(5), 404-416
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., Forman, D. (2011) Global cancer statistics, CA Canc. J. Clin., 61(2), 69-90
Krishnaiah, Y., Satyanarayana, V., Kumar, B. D., Karthikeyan, R. (2002) In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil, Eur. J. Pharm. Sci., 16(3), 185-192
Kumar, M. (2000) Nano and microparticles as controlled drug delivery devices, J. Pharm. Sci., 3(2), 234-258
Leopold, N. (2009) Surface-enhanced Raman Spectroscopy: Selected Applications, Napoca Star
Li, P., Wang, Y., Peng, Z., She, F., Kong, L. (2011) Development of chitosan nanoparticles as drug delivery systems for 5-fluorouracil and leucovorin blends, Carbohydr. Polym., 85(3), 698-704
Longley, D. B., Harkin, D. P., Johnston, P. G. (2003) 5-fluorouracil: mechanisms of action and clinical strategies, Nat. Rev.Cancer, 3(5), 330-338
Mishra, R., Ramasamy, K., Ahmad, N., Eshak, Z., Majeed, A. (2014) pH dependent poly [2-(methacryloyloxyethyl) trimetylammonium chloride-co-methacrylic acid] hydrogels for enhanced targeted delivery of 5-fluorouracil in colon cancer cells, J. Mater. Sci. - Mater. Med., 25(4), 999-1012
Nair, L., Jagadeeshan, S., Nair, S. A., Kumar, G. V. (2011) Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA, Int. J. Nanomedicine, 6, 1685-1697
Ortiz, R., Prados, J., Melguizo, C., Arias, J. L., Ruiz, M. A., Alvarez, P. J., Caba, O., Luque, R., Segura, A., Aranega, A. (2012) 5-Fluorouracil-loaded poly (ε-caprolactone) nanoparticles combined with phage E gene therapy as a new strategy against colon cancer, Int. J. Nanomedicine, 7, 95-107
Park, J. H., Saravanakumar, G., Kim, K., Kwon, I. C. (2010) Targeted delivery of low molecular drugs using chitosan and its derivatives, Adv. Drug Deliv. Rev., 62(1), 28-41
Parkin, D., Pisani, P., Ferlay, J. (1993) Estimates of the worldwide incidence of eighteen major cancers in 1985, Int. J. Cancer, 54(4), 594-606
Subudhi, M. B., Jain, A., Jain, A., Hurkat, P., Shilpi, S., Gulbake A., Jain S. K. (2015) Eudragit S100 coated citrus pectin nanoparticles for colon targeting of 5-fluorouracil, Materials, 8(3), 832-849
Tsai, Y. -M., Chien, C. -F., Lin, L. -C., Tsai, T. -H. (2011) Curcumin and its nano-formulation: the kinetics of tissue distribution and blood–brain barrier penetration, Int. J. Pharm., 416(1), 331-338
van Kuilenburg, A. B., Haasjes, J., Richel, D. J., Zoetekouw, L., van Lenthe, H., De Abreu, R. A., Maring, J. G., Vreken, P., van Gennip, A. H. (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene, Clin. Cancer Res., 6(12), 4705-4712
Wang, J., Peng, C.-A. (2011) Anticancer effectiveness of polymeric drug nanocarriers on colorectal cancer cells, Conf. Proc. IEEE Eng. Med. Biol. Soc., Boston, IEEE, 3249-3252
Wigmore, P. M., Mustafa, S., El-Beltagy, M., Lyons, L., Umka, J., Bennett, G. (2010) Effects of 5-FU, Adv. Exp. Med. Biol., 678, 157-164
Yan, C., Gu, J., Guo, Y., Chen, D. (2010) In vivo biodistribution for tumor targeting of
-Fluorouracil (5-FU) loaded N-succinyl-chitosan (Suc-Chi) nanoparticles, Yakugaku Zasshi, 130(6), 801-804
Yassin, A. E. B., Alsarra, I. A., Alanazi, F. K., Al-Mohizea, A. M., Al-Robayan, A. A., Al-Obeed, A. A. (2010a) New targeted-colon delivery system: in vitro and in vivo evaluation using X-ray imaging, J. Drug. Target., 18(1), 59-66
Yassin, A. E. B., Anwer, M. K., Mowafy, H. A., El-Bagory, I. M., Bayomi, M. A., Alsarra, I. A. (2010b) Optimization of 5-flurouracil solid-lipid nanoparticles: a preliminary study to treat colon cancer, Int. J. Med. Sci., 7(6), 398-408
Zhang, D.-Y., Shen, X.-Z., Wang, J.-Y., Dong, L., Zheng, Y.-L., Wu, L.-L. (2008) Preparation of chitosan-polyaspartic acid-5-fluorouracil nanoparticles and its anti-carcinoma effect on tumor growth in nude mice, World J. Gastroenterol., 14(22), 3554-3562
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2015 Studia Universitatis Babeș-Bolyai Biologia
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
